

## **THE AMENDMENTS**

### **In the Specification**

Amend the paragraph starting at page 5, line 13:

Figure 1 (SEQ ID NO:1) shows an embodiment of a nucleic acid (~~mRNA~~ DNA) which includes a sequence which encodes a differentially expressed protein provided herein, CZA8. Start (ATG) and stop (TGA) codons are underlined. The bold and underlined sequence from nucleic acid 105 to nucleic acid 134 represents sequence that is absent in the splice variant shown in Figure 4 (SEQ ID NO:3).

Figure 4 (SEQ ID NO:3) shows a nucleic acid (~~mRNA~~ DNA) which includes a sequence which encodes an alternative embodiment of CZA8. Start (ATG) and stop (TGA) codons are underlined. The sequence of Figure 4 (SEQ ID NO:3) represents a splice variant of the CZA8 gene; in particular, the sequence of Figure 4 (SEQ ID NO:3) does not encode the bolded and underlined amino acids shown in Figure 2 (SEQ ID NO:2) .

### **In the Claims**

1. (Withdrawn) A method of screening drug candidates comprising:
  - a) providing a cell that expresses an expression profile gene encoding CZA8 or fragment thereof;
  - b) adding a drug candidate to said cell; and
  - c) determining the effect of said drug candidate on the expression of said expression profile gene.
2. (Withdrawn) A method according to claim 1 wherein said expression profile gene encodes the CZA8 sequence of Figure 2 (SEQ ID NO:2).
3. (Withdrawn) A method according to claim 1 wherein said expression profile gene encodes the CZA8 sequence of Figure 5 (SEQ ID NO:4).